Analyst Ratings For Novadaq Technologies (TSE:NDQ)
Today, Royal Bank of Canada lowered its price target on Novadaq Technologies (TSE:NDQ) to per share.
There are 3 buy ratings on the stock.
The current consensus rating on Novadaq Technologies (TSE:NDQ) is Buy (Score: 3.00) with a consensus target price of C$15.42 per share, a potential .
Some recent analyst ratings include
- 2/22/2017-Scotiabank Reiterated Rating of Outperform.
- 11/4/2016-Wedbush Reiterated Rating of Outperform.
- 2/18/2016-Canaccord Genuity Reiterated Rating of Buy.
About Novadaq Technologies (TSE:NDQ)
Novadaq Technologies Inc. is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. The Company’s segment is medical devices. The Company’s SPY fluorescence imaging technology platform (SPY Fluorescence Imaging) provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic. The Company’s products include SPY, SPY Elite, LUNA and PINPOINT Imaging Systems, SPY Analysis Toolkit, DermACELL and SPY-Q Case Manager. DermACELL is an Acellular Dermal Matrix (ADM) that is used in breast reconstruction surgeries, as well as in the treatment of diabetic foot and venous stasis ulcers, and chronic non-healing wounds.
Recent Trading Activity for Novadaq Technologies (TSE:NDQ)
Shares of Novadaq Technologies closed the previous trading session at 9.61 down -0.20 -2.04% with 14,341 shares trading hands.
